PTEN and neoplasm: Treatment with ipatasertib, an AKT inhibitor, and abiraterone showed improved radiographical PFS compared to abiraterone plus placebo in patients with tumor PTEN-loss (18.5 months vs. 16.5 months, HR 0.77; 95% CI 0.61–0.98; p = 0.034) [78].